Skip to main content
SpringerLink
Log in

The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

Since drug candidates with low oral systemic exposure may be due to either or both absorption and metabolism factors, determining what factors limit the oral systemic exposure is not always obvious in a singlein-vivo pharmacokinetic (PK) assay. A rapid ratin-vivo PK screen where the oxidative drug metabolism has been attenuated using the suicide CYP450 inhibitor aminobenzotriazole (ABT) is described. We have shown that the roles of absorption and metabolism for drug candidates with low oral systemic exposure can be determined by comparing the PK parameters of drug candidates orally administered to non-treated and ABT-treated rats. Propranolol, metoprolol and climetidine are used as model drugs. Propranolol and metoprolol have low oral systemic exposures in rats primarily due to metabolism factors while the oral systemic exposure of climetidine is high in rats. For propranolol and metoprolol, large increases in the systemic exposure of these drugs were observed between non-treated and ABT-treated rats. ABT appeared not to increase or decrease significantly the rate and extent of absorption or metabolism of Cimetidine since that oral systemic exposure of non-treated and ABT-treated rats did not significantly change.

These experiments suggest that for drug candidates with low systemic exposures in rats an observation of no change in the oral systemic exposure in ABT-treated rats when compared to the non-treated rats imply that absorption (or formulation) factors limit the systemic exposure of the drug while an increase in the systemic exposure in ABT-treated rats imply that metabolism factors limit the systemic exposure. Due to the ease of preparing and interpreting PK data from ABT-treated rats, is suggested that this assay could be used as an alternative toin vivo cannulation assays. Please send reprint requests to: Dr G. W. Caldwell,

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Caldwell, G. W. (2000). Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. [Published erratum appears in Curr Opin in Drug Discov Develop 2000, 3(2), 250]. Curr Opin in Drug Discov Devel 3(1), 30–41.

    CAS  Google Scholar 

  2. Caldwell, G. W.; Ritchie, D. M.; Masucci, J. A.; Hageman, W. (2001). The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr Top in Med Chem 1(5), 353–366.

    Article  CAS  Google Scholar 

  3. Caldwell, G. W.; Yan, Z.; Masucci, J. A.; Hageman, W.; Ritchie, D. M. (2003). Applied Pharmacokinetics in Drug Development. An Overview of Drug Discovery. Pharm Dev Regul 1(2), 117- 132.

    Google Scholar 

  4. Cox, K. A.; Dunn-Meynell, K.; Korfmacher, W. A.; Broske, L.; Nomeir, A. A.; Lin, C.-C; Cayen, M. N.; Barr, W. H. (1999). Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats. Drug Discovery Today 4(5), 232–237.

    Article  PubMed  CAS  Google Scholar 

  5. Watt A.P., Morrison D., Evans D.C. (2000). Approaches to higher-through pharmacokinetics (HTPK) in drug discovery. Drug discovery Today 5(1), 17–24.

    Article  PubMed  CAS  Google Scholar 

  6. White R.E. (2000). High-through screening in drug metabolism and pharmacokinetics support of drug discovery. Annu Rev Pharmacol Toxicol 40, 133–157.

    Article  PubMed  CAS  Google Scholar 

  7. Masucci, John A.; Caldwell, Gary W.; Jones, William J.; Juzwin, Stephen J.; Sasso, Patrick J.; Evangelisto, Mary. (2001). The use of on-line and off-line chromatographic extraction techniques coupled with mass spectrometry for support of in vivo and in vitro assays in drug discovery. Cur. Topics in Med Chem 1(5), 463–471.

    Article  CAS  Google Scholar 

  8. Chiou, W.L.; Robbie, G.; Chung, S.M.; Wu, T-C; Ma, C. (1998). Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66. Pharm Res 15(9), 1474–1479.

    Article  PubMed  CAS  Google Scholar 

  9. Bachmann, K.; Pardoe, D.; White, D. (1996). Scaling basic toxicokinetic parameters from rat to human. Environ health Perspect 10494), 400–407

    Article  Google Scholar 

  10. Mahmood, I. (2000). Can absolute oral bioavailability in humans be predicted from animals? A comparison of allometry and different indirect methods. Drug Metab Drug Int 16(2), 143–155

    Article  CAS  Google Scholar 

  11. Caldwell, G.W.; Masucci, J.A.; Yan, Z.; Hageman, W. (2004). Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vssand t1/2 be predicted from in-vivo rat data? Eur J Drug Metab Pharm 29(2), 133–143.

    Article  CAS  Google Scholar 

  12. Ortiz de Montellano, Paul R.; Mico, Bruce A.; Mathews, James M.; Kunze, Kent L.; Miwa, Gerald T.; Lu, Anthony Y. H. (1981). Selective inactivation of cytochrome P-450 isozymes by suicide substrates. Archives of Biochemistry and Biophysics 210(2), 717–28.

    Article  PubMed  CAS  Google Scholar 

  13. Balani, Suresh K.; Zhu, Tong; Yang, Tian J.; Liu, Zhi; He, Bing; Lee, Frank W. (2002). Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metabolism and Disposition 30(10), 1059–1062.

    Article  PubMed  CAS  Google Scholar 

  14. Mugford, Cheryl A.; Mortillo, Mildred; Mico, Bruce A.; Tarloff, Joan B. (1992). 1-Aminobenzotriazole-induced destruction of hepatic and renal cytochromes P450 in male Sprague-Dawley rats. Fundamental and Applied Toxicology 19(1), 43–9.

    Article  PubMed  CAS  Google Scholar 

  15. Soltis, Michael; Colby, Howard D. (1998). Inhibition of testicular steroid metabolism by administration of 1-aminobenzotriazole to rats. Pharmacology 56(1), 51–56.

    Article  PubMed  CAS  Google Scholar 

  16. Meschter, C. L.; Mico, B. A.; Mortillo, M.; Feldman, D.; Garland, W. A.; Riley, J. A.; Kaufman, L. S. (1994). A 13-week toxicologic and pathologic evaluation of prolonged cytochromes P450 inhibition by 1-aminobenzotriazole in male rats. Fundamental and Applied Toxicology 22(3), 369–81.

    Article  PubMed  CAS  Google Scholar 

  17. Town, C.; Henderson, L.; Chang, D.; Mortillo, M.; Garland, W. (1993). Distribution of 1-aminobenzotriazole in male rats after administration of an oral dose. Xenobiotica, 23(4), 383–90.

    Article  PubMed  CAS  Google Scholar 

  18. Colby, Howard D.; Abbott, Brian; Cachovic, Michael; Debolt, Kristine M.; Mico, Bruce A. (1995). Inactivation of adrenal cytochromes P450 by 1-aminobenzotriazole. Biochemical Pharmacology 49(8), 1057–62.

    Article  PubMed  CAS  Google Scholar 

  19. Mico, Bruce A.; Federowicz, Debra A.; Ripple, Mary G.; Kerns, William. (1988). In vivo inhibition of oxidative drug metabolism by, and acute toxicity of, 1-aminobenzotriazole (ABT). A tool for biochemical toxicology. Biochemical Pharmacology 37(13), 2515–19.

    Article  PubMed  CAS  Google Scholar 

  20. Mico, Bruce A.; Federowicz, Debra Ann; Burak, Eric; Swagzdis, James E. (1987). In vivo inhibition of phenacetin oxidation by suicide substrate 1 -aminobenzotriazole. Drug Metabolism and Disposition 15(2), 274–6.

    PubMed  CAS  Google Scholar 

  21. Mugford, Cheryl A.; Tarloff, Joan B. (1997). The contribution of oxidation and deacetylation to acetaminophen nephrotoxicity in female Sprague-Dawley rats. Toxicology Letters 93(1), 15–22.

    Article  PubMed  CAS  Google Scholar 

  22. Henesey, Caroline M.; Harvison, Peter J. (2002). Renal damage, metabolism and covalent binding following administration of the nephrotoxicant N-(3, 5-dichlorophenyl)succinimide (NDPS) to male Fischer 344 rats. Toxicology 170(3), 187–200.

    Article  PubMed  CAS  Google Scholar 

  23. Shargel, L.; Yu, A.B.C. (1993). Applied Biopharmaceutical and Pharmacokinetics, 3rd Edition, Appleton and Lange, Stamford, CT.

    Google Scholar 

  24. Miller, J.C.; Miller, J.N. (1992). Statistics for analytical chemistry, 2nd Edition, Ellis Hardwood Limited, West Sussex, England.

    Google Scholar 

  25. Belpaire, F. M.; Smet, F. DE.; Vynckier, L. J.; Vermeiden, A. M.; Rosseel, M. T.; Bogaert, M. G.; Chauvelot-Moachon, L. (1990). Effect of aging on the pharmacokinetics of atenolol, metoprolol and propranolol in the rat. J Pharmacol Exp Therapeutics 254(1), 116–122.

    CAS  Google Scholar 

  26. Shibasaki, S.; Asahina, M.; Kawamata, Y.; Kojo, M.; Nishigaki, R.; Umemura, K. (1989). The inhibitor effects of Cimetidine on elimination and distribution of propranolol in rats. J. Pharmacobio-Dyn 12, 549–557.

    Article  PubMed  CAS  Google Scholar 

  27. Weiner, I.M.; Roth, L. ( 1981 ). Renal excretion of Cimetidine. J Pharmacol Exp Therapeutics 216(3), 516–520.

    CAS  Google Scholar 

  28. Knodell, R.G.; Browne, D.; Gwodz, G.P.; Brian, W.R.; Guengerich, F.P. (1991). Differential inhibition of human liver cytochrome P-450 by Cimetidine, Gastroenterology 101, 1680–1691.

    PubMed  CAS  Google Scholar 

  29. Griffiths, R.; Lewis, A.; Jeffrey, P. (1996). Models of drug absorption in situ and in conscious animals. Chapter 5 in Models for Assessing Drug Absorption and Metabolism, Eds. Borchardt, Smith and Wilson, Plenum Press, New York, page 67–82.

    Google Scholar 

  30. Akrawi, S.H.; Wedlung, P.J. (1987). Method for chronic portal vein infusion in unrestrained rats. J Pharmacol Methods 17(1), 67–74.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Welsh & McKean Roads, P.O. Box 776, PA 19477, Spring House, USA

    Gary W. Caldwell, David M. Ritchie, John A. Masucci, William Hageman, Carlos Cotto, Jeffrey Hall, Becki Hasting & William Jones

Authors
  1. Gary W. Caldwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David M. Ritchie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John A. Masucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William Hageman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carlos Cotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jeffrey Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Becki Hasting
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. William Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David M. Ritchie.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caldwell, G.W., Ritchie, D.M., Masucci, J.A. et al. The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens. Eur. J. Drug Metab. Pharmacokinet. 30, 75–83 (2005). https://doi.org/10.1007/BF03226411

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03226411

Keywords

Search

Navigation